Head-to-Head Comparison of [ 68 Ga]Ga-DOTA.SA.Fibroblast Activation Protein Inhibitor (FAPi) and [ 68 Ga]Ga-DOTANOC Positron Emission Tomography/Computed Tomography Imaging for the Follow-Up Surveillance of Patients with Medullary Thyroid Cancer
Authors' conclusion
[68Ga]Ga-DOTA.SA.FAPi outperformed [68Ga]Ga-DOTANOC PET/CT in the detection of distant metastases with both patient-based and lesion-based analysis in MTCs.
Study context
- Population
- Patients with MTC undergoing follow-up assessment; findings validated with diagnostic CT; 21 males, 6 females, mean age 42.4 ± 13.2 years (range 14–66)
- Participants
- 27 patients
- Comparison
- [68Ga]Ga-DOTA.SA.FAPi vs [68Ga]Ga-DOTANOC positron emission tomography (PET)/CT
- Outcome
- Detection efficiency (sensitivity) for primary and metastatic MTC lesions
Methodological detailshead-to-head comparison, patient-based and lesion-based analysis
- Head-to-head comparison
- Patient-based and lesion-based analysis
Performance
As reported in the abstract
Similar sensitivity for brain metastases
100%
Further findings
SULpeak and tumor-to-background ratios (TBR)
- Higher uptake values and TBR with [68Ga]Ga-DOTA.SA.FAPi vs [68Ga]Ga-DOTANOC
Original publication
Head-to-Head Comparison of [ 68 Ga]Ga-DOTA.SA.FAPi and [ 68 Ga]Ga-DOTANOC Positron Emission Tomography/Computed Tomography Imaging for the Follow-Up Surveillance of Patients with Medullary Thyroid Cancer. Thyroid. Published 1 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →